Title

Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    163
Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence.
Study Started
Oct 31
2006
Primary Completion
Jul 31
2008
Study Completion
Jul 31
2008
Last Update
Dec 31
2018

Drug Probuphine

4 implants

Drug placebo

4 implants

Group A Active Comparator

Group B Placebo Comparator

Criteria

Inclusion Criteria:

Voluntarily provide written informed consent prior to the conduct of any study related procedures
Male or female, 18-65 years of age
Meet DSM-IV criteria for current opioid dependence
Females of childbearing potential and fertile males must use a reliable means of contraception

Exclusion Criteria:

Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS)
Presence of aspartate aminotransferase (AST) levels ≥ 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels ≥ 3 X upper limit of normal and/or total bilirubin ≥ 1.5 X upper limit of normal and/or creatinine ≥ 1.5 X upper limit of normal
Received treatment for opioid dependence (e.g., methadone, BPN), within the previous 90 days
Current diagnosis of chronic pain requiring opioids for treatment
Candidates for only short term opioid treatment or opioid detoxification therapy
Pregnant or lactating females
Previous hypersensitivity or allergy to BPN- or EVA-containing substances or naloxone
Current use of agents metabolized through CYP 3A4 such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)
Current anti-coagulant therapy (such as warfarin) or an INR > 1.2
Meet DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives)
Current use of benzodiazepines other than physician prescribed use
Significant medical or psychiatric symptoms or dementia which in the opinion of the Investigators would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent
Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study
Participated in a clinical study within the previous 8 weeks
No Results Posted